Pfizer

News

Lilly's breast cancer drug Verzenio approved in EU

Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.

News

FDA says Clovis' Rubraca could be prostate cancer breakthrou...

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.

News

Pfizer CEO Read to step down, COO Bourla takes the helm

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla.

News

US regulator backs Pfizer's Vizimpro lung cancer drug

The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation.

News

Pharma depriving developing countries of taxes - report

A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually.

News

Pfizer/Merck KGaA eye fast review for kidney cancer combo

A combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage trial in untreated but advanced kidney cancer.

Lilly's breast cancer drug Verzenio approved in EU

FDA says Clovis' Rubraca could be prostate cancer breakthrou...

Pfizer CEO Read to step down, COO Bourla takes the helm

US regulator backs Pfizer's Vizimpro lung cancer drug

Pharma depriving developing countries of taxes - report

Pfizer/Merck KGaA eye fast review for kidney cancer combo

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

Pfizer

Editor's Picks